Papi A, Vestbo J, Fabbri L, et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet. 2018;391:1076-84. ,Fabbri L, Singh D, Valente I, Alessandro Guasconi, et al. Extrafine single inhaler triple therapy improves quality of life in COPD. Analysis of SGRQ subdomains of the TRIBUTE Study. ERS 2018, Parijs. Sessie 244; OA2131.
Meer aandacht en zorg voor palliatieve zorgverleners nodig
mei 2024